NL-OMON46698已完成3 期
A multicenter, randomized, open label, efficacy assessor-blinded study of risankizumab compared to secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systematic therapy. - M16-766
AbbVie0 个研究点目标入组 11 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Laboratory values meeting the following criteria within the screening period prior to the first dose of study drug:
- •Serum aspartate transaminase (AST) < 2 × ULN;
- •Serum alanine transaminase (ALT) < 2 × ULN;
- •Serum direct bilirubin <= 2.0 mg/dL; except for subjects with isolated elevation of indirect bilirubin relating to a confirmed diagnosis of Gilbert syndrome;
- •Total white blood cell (WBC) count > 3,000/µL;
- •Absolute neutrophil count (ANC) > 1,500/µL;
- •Platelet count > 100,000/µL;
- •Hemoglobin > 8 g/dL.;2. Diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months before the Baseline Visit;;3. Subject has stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis
- •Subject has >= 10% BSA psoriasis involvement, sPGA score of >= 3, and PASI >= 12 at Screening and Baseline Visit;;4. Subject must be a candidate for systemic therapy as assessed by the investigator;;5. Subject must be an acceptable candidate to receive secukinumab according to the local label for this compound.
排除标准
- •1. No history of:
- •Erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis;
- •Active skin disease other than psoriasis that could interfere with the assessment of psoriasis;
- •Chronic infections including HIV, viral hepatitis (hepatitis B, hepatitis C), and/ or active tuberculosis. Subjects with a positive QuantiFERON®-TB /PPD test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines. The patient will not be eligible for randomization if latent tuberculosis is present and is untreated as per local guidelines.
- •Active systemic infection during the last 2 weeks prior to Baseline Visit (exception: common cold) prior to Baseline Visit, as assessed by the investigator;;2. No history of any documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix;;3. No previous exposure to risankizumab;;4. No previous exposure to secukinumab;;5. Subject must not have been treated with any investigational drug within 30 days or 5 half lives of the drug (whichever is longer) prior to the first dose.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS®) and Ribavirin (COPEGUS®) Therapy in Patients with Genotype 1-Chronic Hepatitis C and Non-Response to a Previous Course of Peg-Interferon alfa-/Ribavirin Combination (ATRACTION) - ATRACTIOEUCTR2006-005500-14-DEniversitätsmedizin der Johannes-Gutenberg Universität Mainz
进行中（未招募）
1 期
Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque-Type PsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersPlaque PsoriasisEUCTR2017-004932-12-DEAbbVie Deutschland GmbH & Co. KG310
进行中（未招募）
1 期
Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque-Type PsoriasisPlaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2017-004932-12-ITABBVIE DEUTSCHLAND GMBH & CO. KG310
进行中（未招募）
1 期
Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque-Type PsoriasisPlaque PsoriasisEUCTR2017-004932-12-GBAbbVie Deutschland GmbH & Co. KG310
进行中（未招募）
1 期
Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque-Type PsoriasisPlaque PsoriasisEUCTR2017-004932-12-ESAbbVie Deutschland GmbH & Co. KG310